Pay in 4 interest-free payments of $6.50 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Nutrients 11 , 12041217 (2019)
Gopi, S., & Balakrishnan, P
Side Effects of Retatrutide: What the Trial Data Shows Retatrutides side effect profile is broadly consistent with other GLP-1 medications, with additional considerations at higher doses
Why this trial matters : First oral SERD to succeed in Phase III in early breast cancer Signals a potential new adjuvant standard of care Advances endocrine therapy beyond legacy agents Johnson & Johnson Tecvayli + Darzalex Faspro Shows Unprecedented Phase III Success in Relapsed/Refractory Multiple Myeloma The Phase III MajesTEC-3 trial demonstrated that the combination of Tecvayli (teclistamab) plus Darzalex Faspro (daratumumab SC) significantly improved progression-free survival and overall survival versus standard regimens in patients with relapsed/refractory multiple myeloma as early as second-line, with an ~83% reduction in disease progression or death at almost three years follow-up
US$ 22.23
US$ 20.61
US$ 27.77
US$ 21.28
US$ 25.92
US$ 22.90
US$ 22.04
US$ 22.96
